The VOLTAGE (14) study, analyzing tumor tissue at baseline, post-NCRT, and post-3 cycles of immunotherapy, found higher pCR rates in patients with baseline tumor PD-L1 tumor positive score (TPS) ≥1% and dynamically increasing CD8/Treg ratio. The gene discussed is CD8A; the disease is neoplasm.